Ignite Creation Date:
2025-12-24 @ 1:32 PM
Ignite Modification Date:
2025-12-29 @ 1:32 PM
Study NCT ID:
NCT02997995
Status:
COMPLETED
Last Update Posted:
2020-09-30
First Post:
2016-12-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure
Sponsor:
UNICANCER
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-15
Start Date Type:
ACTUAL
Primary Completion Date:
2019-07-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-08-28
Completion Date Type:
ACTUAL
First Submit Date:
2016-12-09
First Submit QC Date:
None
Study First Post Date:
2016-12-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-09-29
Last Update Post Date:
2020-09-30
Last Update Post Date Type:
ACTUAL